TrialSignal
Clinical trial intelligence report
NYSCF Scientific Discovery Biobank
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT06203106-Jul 28, 2026
NCT ID
NCT06203106
Status
RECRUITING
Phase
registry-stage
Sponsor
New York Stem Cell Foundation Research Institute
Executive brief
Investment-Ready Snapshot
NYSCF Scientific Discovery Biobank is a registry-stage clinical asset sponsored by New York Stem Cell Foundation Research Institute in ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder. SEO and diligence focus: Biological Sample Collection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06203106
Indication
ALS
Modality
protein therapy
Target
Biological Sample Collection
Intervention
Biological Sample Collection
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.